ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 93.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-06-01
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was -833.00K shares.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 375.00K shares, a 12.28% increase year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 267.00K shares, a 7.23% increase year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 284.00K shares, a 1.73% decline year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 93.00K shares, a 2.20% increase from fiscal 2024.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 91.00K shares, a 88.45% decline from fiscal 2023.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 788.00K shares, a 87.62% increase from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 420.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -833.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -458.00K shares derived: sum of 2 quarters · filed 2026-06-01 | -191.00K shares derived: sum of 3 quarters · filed 2026-06-01 | 93.00K shares 10-K · filed 2026-06-01 | |
| 2025-09-30 | 375.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | 642.00K shares derived: sum of 2 quarters · filed 2025-11-19 | 926.00K shares 10-Q · filed 2025-11-19 | 145.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-06-30 | 267.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 551.00K shares 10-Q · filed 2025-08-13 | -230.00K shares derived: sum of 3 quarters · filed 2026-06-01 | 104.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2025-03-31 | 284.00K shares 10-Q · filed 2025-05-20 | -497.00K shares derived: sum of 2 quarters · filed 2026-06-01 | -163.00K shares derived: sum of 3 quarters · filed 2026-06-01 | 86.00K shares derived: sum of 4 quarters · filed 2026-06-01 | |
| 2024-12-31 | -781.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -447.00K shares derived: sum of 2 quarters · filed 2026-06-01 | -198.00K shares derived: sum of 3 quarters · filed 2026-06-01 | 91.00K shares 10-K · filed 2026-06-01 | 910.00K shares 10-K · filed 2025-04-01 |
| 2024-09-30 | 334.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 583.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 872.00K shares 10-Q · filed 2024-11-13 | 915.63K shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2024-06-30 | 249.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 538.00K shares 10-Q · filed 2024-08-14 | 581.63K shares derived: sum of 3 quarters · filed 2025-04-01 | 581.63K shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2024-03-31 | 289.00K shares 10-Q · filed 2024-05-10 | 332.63K shares derived: sum of 2 quarters · filed 2025-04-01 | 332.63K shares derived: sum of 3 quarters · filed 2025-04-01 | 332.63K shares derived: sum of 4 quarters · filed 2025-04-01 | |
| 2023-12-31 | 43.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | 43.63K shares derived: sum of 2 quarters · filed 2025-04-01 | 43.63K shares derived: sum of 3 quarters · filed 2025-04-01 | 788.00K shares 10-K · filed 2025-04-01 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-13 | 744.37K shares 10-Q · filed 2023-11-13 | 1.14M shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 744.37K shares 10-Q · filed 2023-08-11 | 1.14M shares derived: sum of 3 quarters · filed 2024-03-29 | 1.14M shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-03-31 | 744.37K shares 10-Q · filed 2023-05-12 | 1.14M shares derived: sum of 2 quarters · filed 2024-03-29 | 1.14M shares derived: sum of 3 quarters · filed 2024-03-29 | 1.14M shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2022-12-31 | 400.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 400.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 400.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 420.00K shares 10-K · filed 2024-03-29 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-10 | 20.00K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 20.00K shares 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 20.00K shares 10-Q · filed 2022-05-13 | ||||
| 2017-12-31 | 13.00K shares 10-K/A · filed 2018-08-20 | ||||
| 2016-12-31 | 14.00K shares 10-K/A · filed 2018-08-20 | ||||
| 2015-12-31 | 27.00K shares 10-K/A · filed 2018-08-20 | ||||
| 2014-12-31 | 46.00K shares 10-K · filed 2017-02-24 | ||||
| 2013-12-31 | 64.00K shares 10-K · filed 2016-03-29 | ||||
| 2012-12-31 | 41.00K shares 10-K · filed 2015-03-27 | ||||
| 2011-12-31 | 187.00K shares 10-K · filed 2014-03-27 | ||||
| 2010-12-31 | 1.04M shares 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |